Spotlight discussion - Tackling the two-speed Europe in access to care
Information
- Availability of a number of treatments varies across the EU. What are the root causes of these discrepancies, and how much are late market assessments, evidence requirements, and pricing and reimbursement policies to blame?
- What is the role of policymakers and industry in tackling this — mainly East-West — gap? Has COVID-19 reinforced these inequalities?
- What is the impact of unequal access to treatments on survival rates? Which patients are particularly vulnerable? What does it mean for the EU’s values and unity?
- Can the health union narrow these discrepancies? And how much can health outcomes inequalities be reduced when economic inequalities are so marked between member countries, and health systems remain so distinct?
Speakers
Mark Lawler
associate pro-vice-chancellor and professor of digital healthQueen's University BelfastCristian Silviu Bușoi
MEP (EPP, Romania)European ParliamentMartin Price
vice president of health economics, market access and reimbursementin in EMEAJanssenStanimir Hasardzhiev
secretary generalPatient Access PartnershipModerator: Carlo Martuscelli
reporterPOLITICORegistered attendees
FB
Francesco Bordone
European Commission